Wolf-man jack
17時間前
WQLF SAYS: In other words, Charlottes Web was chosen for the Medicare Pilot Program because of the new BAT / CWBHF Director's Connection to the POTUS, and not on the merit of their Products. Now it makes sense why MMJ International was suing the CMS for choosing Charlottes Web because their products were not up to par according to their Press Releases. Could it be that is why CV SCIENCES and other CBD companies announced they were in a position to participate in the Program? How many CBD companies do you think will be able to sell their products once the program is completed? Now We understand YQU Understand. Have Mercy WQLF ahoooooo
Dr. Joong J Fang Said: Nice Find WQLF. If Other CBD companies are positioning their concerns for the CMS Medicare Pilot Program, then the goal would be to approach Doctors, because they will be the individuals that can recommend the CBD Company of their choice. Charlottes Web is in a better position because they are using their products as we are told. How can the other CBD companies products be approved by Doctor's if their products are not being utilized in the Pilot Program, or are they ? Would GRAS Certification be a Qualification. CV SCIENCES and the ITSY BITSY Spider Web company are the only two companies that have that certification. The CMS Pilot Program has not been too transparent at this stage of the game. Will the MMJ International lawsuits put a bad taste in the minds of the Doctors from their recent Press Releases? We shall see.
Q:What products does CV SCIENCES have to offer Senior citizens in the CMS MEDICARE PILOT program ?
Ai Generated:
CV Sciences has many products that align with the guidelines of the CMS Substance Access Beneficiary Engagement Incentive (BEI) pilot program. While specific covered items depend on physician direction, seniors can access orally administered, compliant hemp-derived products for symptoms like pain, sleep, and anxiety up to $500 per year.
Qualifying Product Categories
The CMS pilot sets strict requirements: products must be orally administered (tinctures, gummies, softgels) and contain no more than 0.3% delta-9 THC and no more than 3 mg of THC per serving. CV Sciences' nationally available lines are formulated to fit these criteria:
CBD Oils & Liquids: Full-spectrum and broad-spectrum tinctures offer easily measurable, oral dosing.
CBD Gummies: Orally administered, pre-dosed edibles designed for daily wellness, sleep, or stress support.
CBD Softgels: Easy-to-swallow capsules containing naturally legal hemp extracts
.How to Participate & Access Products
Through the CMS pilot, eligible hemp products are not purchased over the counter at retail prices. Instead, they must be:Prescribed or furnished directly by a qualified physician affiliated with an Accountable Care Organization (ACO) or participating CMS Innovation Center model.Used as part of a structured care plan for qualifying beneficiaries.
Because CV Sciences manufactures evidence-backed, third-party tested hemp extracts with Generally Recognized as Safe (GRAS) status, their offerings are well-positioned for integration by participating CMS clinicians.
Q: Is CBDistillery in a position to participate in the CMS Medicare Pilot Program?
Ai Generated:
Yes, CBDistillery is positioned to participate in the CMS Medicare pilot, provided its products meet the strict manufacturing and quality benchmarks required by the program.To successfully take part, the company would have to navigate the following requirements:What the Pilot Actually Is: The CMS Innovation Center launched the Substance Access Beneficiary Engagement Incentive (BEI). It is not a direct insurance coverage or reimbursement for individuals to buy CBD on their own; instead, it allows physicians in qualifying Medicare models to provide approved, hemp-derived CBD products to patients
.Product Qualifications: To be eligible, the CBD must be orally administered, contain less than \(\text{0.3\%}\) delta-9 THC, and have 3 mg or less of THC per serving. The items must also be manufactured like dietary supplements, third-party tested, and entirely free of contaminants.The Sourcing Dynamic: Medicare does not directly pay for the products. Instead, participating healthcare organizations purchase the qualifying CBD products from authorized providers or brands and supply them—up to $500 a year per beneficiary—as part of structured, physician-guided care.CBDistillery’s broad adherence to stringent manufacturing practices aligns well with these federal guidelines. Competitors in the space (like Charlotte’s Web and NuLeaf Naturals) have already taken steps to qualify for or supply products through this CMS initiative.
What has Nuleaf Naturals done in order to participate in the CMS Medicare Pilot Program?
Ai Generated:
To participate in the CMS Medicare pilot program, NuLeaf Naturals is actively reaching out to Accountable Care Organizations (ACOs) and oncology practices to serve as an approved product supplier.To qualify for the program, the company has had to ensure their hemp-derived CBD products meet strict CMS safeguards:THC Limits: Containing no more than 0.3% delta-9 THC and not exceeding 3 mg of total THC per serving.Product Types: Offering only orally administered products, as inhalable items are strictly prohibited.Safety & Compliance: Providing legally sourced, naturally derived cannabinoids backed by rigorous third-party lab testing for potency and contaminants.NuLeaf Naturals intends to leverage this program to supply eligible Medicare beneficiaries who are seeking hemp-derived therapies through their doctors.
Q: Are there other CBD companies that will be involved with the CMS Medicare Pilot Program?
Ai Generated
Yes, the Medicare Advantage pilot program for CBD is likely to involve more than one company. While Charlotte's Web has been announced as a premier partner for the program, other industry players are actively positioning themselves to participate in this initiative.
Here are the key details regarding participants and the scope of the program:
Key Participant (Charlotte's Web): The company has announced its partnership with the Center for Medicare and Medicaid Innovation (CMMI) to provide hemp-derived CBD products, specifically for senior oncology patients, beginning in early 2026.
Industry Positioned to Participate: Other companies, such as High Tide (through its brands NuLeaf Naturals and FAB CBD), are developing Medicare-aligned product categories in anticipation of participating in this new Medicare Advantage supplemental benefit. Additionally, CV Sciences, Inc. has stated it is "strongly positioned to participate" in the pilot program.
Regulatory Requirements: The program will require strict compliance and quality standards, which suggests that only companies with rigorous, audited, and compliant products (such as those with Good Manufacturing Practices) will likely be involved.
Structure: The initiative is designed to test how CBD fits into Medicare's financial and clinical structure, suggesting a, potentially, multi-vendor approach to evaluate different products.
The program is expected to launch as early as April 2026, offering up to $500 in annual coverage for eligible seniors.
CA Market News
5日前
Charlotte's Web Announces Board Transition as Co-Founder Jared Stanley Deepens Focus on DeFloriaJune 5, 2026 5:35 PM
NewsfileMr. Stanley to dedicate his full attention to advancing DeFloria's FDA Phase 2 botanical drug program, a Charlotte's Web-affiliated clinical-stage ventureLouisville, Colorado--(Newsfile Corp. - June 5, 2026) - Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF) ("Charlotte's Web" or the "Company"), a botanical wellness innovation company and a market leader in hemp extract wellness, today announced that co-founder Jared Stanley has stepped down from its Board of Directors, effective June 3, 2026, to dedicate his full attention to his role as Chief Executive Officer of DeFloria, Inc. ("DeFloria"), the clinical-stage botanical pharmaceutical company co-founded by Charlotte's Web. Mr. Stanley's decision is supported by management and the Board.A member of the founding family that created Charlotte's Web, Mr. Stanley has helped shape the Company since its earliest days and has been instrumental in advancing its cultivation, genetics, and regulatory initiatives. He will remain closely connected to Charlotte's Web and available to support and advise the Company where its cultivation and regulatory work intersect with DeFloria's drug development. As a co-founder and shareholder in DeFloria, Charlotte's Web continues to participate directly in the progress of DeFloria's clinical-stage pipeline.Jared Stanley is also a representative on ONE HEMP, co-founded by Charlotte's Web, the national industry coalition advancing responsible federal hemp regulation and consumer protection, and will continue in that role. "On behalf of the entire Board and management team, we thank Jared for his vision and his many contributions as a founder of Charlotte's Web. Charlotte's Web and DeFloria are intertwined, and we fully support Jared as he turns his focus to advancing and financing DeFloria's clinical mission. We look forward to seeing both companies continue to grow and to serve the patients, families, and shareholders who depend on them," said Angela McElwee, Chair of the Board of Charlotte's Web.DeFloria: The OpportunityDeFloria is an FDA Phase 2 clinical-stage botanical pharmaceutical company developing AJA001 oral solution, an investigational botanical drug being developed for irritability associated with autism spectrum disorder, a condition that currently lacks adequate approved treatment options. Formed in 2023 by Charlotte's Web and AJNA BioSciences PBC, with a subsidiary of British American Tobacco p.l.c. as lead investor, DeFloria is advancing AJA001 through the U.S. Food and Drug Administration's Botanical Drug Pathway using Charlotte's Web's proprietary full-spectrum hemp genetics.The 2025 U.S. executive actions are expected to further support cannabinoid drug development by expanding research access, encouraging institutional investment, and reducing barriers to pharmaceutical partnerships. As a co-founder and shareholder in DeFloria, Charlotte's Web is positioned to participate in this opportunity alongside its core botanical wellness business."Stepping back from the Board allows me to put my full energy into DeFloria at a pivotal moment, as we advance AJA001 through Phase 2 and federal policy increasingly recognizes the therapeutic potential of cannabinoids. Charlotte's Web and DeFloria are deeply connected, and the progress we make at DeFloria is progress for Charlotte's Web and its shareholders," said Jared Stanley, Chief Executive Officer of DeFloria and Co-Founder of Charlotte's Web.Following Mr. Stanley's resignation, the Board will have six directors.About Charlotte's Web Holdings, Inc.Charlotte's Web Holdings, Inc., a Certified B Corporation headquartered in Louisville, Colorado, is a botanical wellness innovation company and a market leader in hemp extract wellness that includes Charlotte's Web whole-plant full-spectrum CBD extracts as well as broad-spectrum CBD and cannabinoid isolates. The Company's hemp extracts have naturally occurring botanical compounds including cannabidiol ("CBD"), CBN, CBC, CBG, THC, terpenes, flavonoids, and other beneficial compounds. Charlotte's Web product categories include CBD oil tinctures (liquid products), CBD gummies (sleep, calming, exercise recovery, immunity), CBN gummies, hemp-derived THC microdose gummies, functional mushroom gummies, CBD capsules, CBD topical creams, and lotions, as well as CBD pet products for dogs. Through its substantially vertically integrated business model, Charlotte's Web maintains stringent control over product quality and consistency with analytic testing from soil to shelf for quality assurance. Charlotte's Web products are distributed to retailers and healthcare practitioners throughout the U.S.A. and are available online through the Company's website at www.charlottesweb.com.Shares of Charlotte's Web trade on the TSX under the symbol "CWEB" and are quoted in U.S. Dollars in the United States on the OTCQX under the symbol "CWBHF". For more information:Cory Pala
Director of Investor Relations
(720) 484-8930
Cory.Pala@CharlottesWeb.comForward-Looking InformationCertain information provided herein constitutes forward-looking statements or information (collectively, "forward-looking statements") within the meaning of applicable securities laws. Forward-looking statements are typically identified by words such as "may," "will," "should," "could," "anticipate," "expect," "project," "estimate," "forecast," "plan," "intend," "target," "believe" and similar words suggesting future outcomes or statements regarding an outlook. Forward-looking statements are not guarantees of future performance and readers are cautioned against placing undue reliance on forward-looking statements. This press release includes forward-looking statements including: the future performance or achievements of DeFloria, Inc.; future clinical trial results, therapeutic efficacy, or regulatory approvals of AJA001 oral solution; the anticipated effects of changes in the regulatory environment, including the reclassification of cannabis to Schedule III; and the continuing relationship between the Company and DeFloria, the results of which may be materially different from those expressed or implied by the forward-looking statements contained in this press release.By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties, and other factors which may cause actual results, levels of activity, and achievements to differ materially from those expressed or implied by such statements. The forward-looking statements contained in this press release are based on certain assumptions and analysis by management of the Company in light of its experience and perception of historical trends, current conditions and expected future developments and other factors that management believes are appropriate and reasonable.The material factors and assumptions used to develop the forward-looking statements herein include, but are not limited to: regulatory regime changes; anticipated product development and sales; the success of sales and marketing activities; product development and production expectations; outcomes from R&D activities; the Company's ability to deal with adverse growing conditions in a timely and cost-effective manner; the availability of qualified and cost-effective human resources; compliance with contractual and regulatory obligations and requirements; availability of adequate liquidity and capital to support operations and business plans; and expectations around consumer product demand. In addition, the forward-looking statements are subject to risks and uncertainties pertaining to, among other things: supply and distribution chains; the market for the Company's products; revenue fluctuations; regulatory changes; loss of customers and retail partners; retention and availability of talent; competing products; share price volatility; loss of proprietary information; product acceptance; internet and system infrastructure functionality; information technology security; available capital to fund operations and business plans; crop risk; economic and political considerations; and including but not limited to those risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ending December 31, 2025, and other risk factors contained in other filings with the Securities and Exchange Commission available at http://www.sec.gov and filings with Canadian securities regulatory authorities available at www.sedarplus.ca. The impact of any one risk, uncertainty, or factor on a particular forward-looking statement is not determinable with certainty as these are interdependent, and the Company's future course of action depends on management's assessment of all information available at the relevant time.Any forward-looking statement in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. Except as required by applicable law, the Company assumes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. All forward-looking statements, whether written or oral, attributable to the Company or persons acting on the Company's behalf, are expressly qualified in their entirety by these cautionary statements.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300369 Original: Charlotte's Web Announces Board Transition as Co-Founder Jared Stanley Deepens Focus on DeFloria
DarthYoda
5日前
Three different topics below...
1.) OTC Markets officially updated the Share Structure yesterday just before the close. TSX approved. Company is now debt free. As explained a while back, the Unrestricted Shares barely changed at all. Still ~142mil. Now whenever BAT(BTI) feels like it, they can also buy shares in the open market to increase their 40.6% to 49.9%. That 9.3% should equate to around another 25million shares...
Share Structure
Market Cap 112,765,211 06/04/2026
Authorized Shares Unlimited 05/28/2026
Outstanding Shares 270,549,931 05/28/2026
Restricted 127,636,707 05/28/2026
Unrestricted 142,913,224 05/28/2026
Held at DTC 68,534,933 05/28/2026
Float 142,878,333 04/14/2026
https://www.otcmarkets.com/stock/CWBHF/security
2.) EXECUTIVE OFFICE OF THE PRESIDENT
OFFICE OF MANAGEMENT AND BUDGET:
WASHINGTON, D.C. 20503
June 4, 2026
STATEMENT OF ADMINISTRATION POLICY
https://www.whitehouse.gov/wp-content/uploads/2026/06/H.R.-8646-SAP_Updated.pdf
3.) "Comparing cannabinoid extracts for treating cancer-related symptoms: a randomized placebo-controlled, triple-blind aggregate n-of-1 clinical trial":
Posted June 02, 2026
Abstract
Context: Despite widespread use of medical cannabinoids for cancer-related symptom management, systematic reviews consistently call for more clinical trial evidence.
Objectives: This study aimed to determine and explore responses to medical cannabis extracts for cancer-related symptoms using patient-centred methodology.
Methods: An aggregate N-of-1 study of clinically stable but symptomatic outpatients from 8 Canadian cancer centres, comparing three blinded sublingual extracts (THC; CBD; 1:1) with placebo, self-titrated within a prescribed schedule for four consecutive days each in randomized sequence for up to three cycles (total 16-48 days). The primary outcome was the frequency of at least a 1.4-point (20%) improvement in a 7-point Patient Global Impression of Change (PGIC) for at least one extract over placebo.
Results: The primary outcome was achieved in 50/89 (56%) participants (p<0.001), with no significant preference of one extract over another on average, but a clear preference between extracts for most individuals. Changes in a modified Edmonton Symptom Assessment score and participant preference (n=91) confirmed these findings. Improved sleep, tiredness and anxiety contributed most to the overall improvement regardless of primary symptom. There were no demographic predictors of response. Mild adverse effects were common with all extracts including placebo but resolved rapidly on dose reduction/cessation. Moderate/severe adverse effects were rare but associated with THC.
Conclusions: Medical cannabis extracts can be meaningfully beneficial for cancer-related symptoms in approximately 50% of patients, particularly for sleep and related symptoms. A starting dose of 2.5mg of THC/CBD three times a day was well-tolerated. Personalization of treatment is required to optimize response.
Key Messages: Three cannabinoid extracts (THC; CBD; and 1:1) were significantly more effective than placebo based on a Patient Global Impression of Change, a modified Edmonton Symptom Assessment System and participant preference. The most helpful extract differed between individuals. Benefits were mostly in sleep, anxiety, and daytime tiredness irrespective of primary symptom.
https://www.medrxiv.org/content/10.64898/2026.05.31.26354558v1
CA Market News
1週前
Charlotte's Web Appoints Jeff Raborn to Board of DirectorsJune 1, 2026 5:35 PM
NewsfileVeteran Legal and Regulatory Executive Brings More Than 25 Years of Experience Across Private Practice and Highly Regulated Consumer IndustriesLouisville, Colorado--(Newsfile Corp. - June 1, 2026) - Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF) (Charlotte's Web or the Company), a botanical wellness innovation company and a market leader in hemp extract wellness, is pleased to announce the appointment of Jeff Raborn to its Board of Directors, effective May 28, 2026. Mr. Raborn has been designated to the Board by BT DE Investments Inc. ("BAT"), a subsidiary of British American Tobacco p.l.c. (LSE: BATS) (NYSE: BTI), in connection with the Company's previously announced transaction with BAT that closed on May 28, 2026 (the "Transaction").Mr. Raborn has served since March 2018 as Executive Vice President, Law & External Affairs and General Counsel of Reynolds American, Inc., a subsidiary of British American Tobacco p.l.c., where he oversees the company's legal, regulatory, and external affairs functions. He joined Reynolds American in 2004 and, prior to assuming his current role, served as Senior Vice President, Litigation and Regulatory, and Deputy General Counsel within the RAI Group. Mr. Raborn also previously served as Chairman of the Reynolds American Foundation.Prior to joining Reynolds, Mr. Raborn practiced law in New Orleans and Baton Rouge, representing clients including Ford, Hyundai, Toyota, Kia, Black & Decker, Exxon, and Shell in product and premises liability matters. He also represented Exxon, Texaco, Shell, and Chevron before the Louisiana Public Service Commission. Mr. Raborn earned a bachelor's degree in history and a Juris Doctor from Louisiana State University."Jeff’s extensive legal, regulatory, and governance experience across highly regulated consumer industries brings valuable insight to the Board as we navigate an increasingly dynamic regulatory environment. His appointment also further strengthens our strategic relationship with BAT and reflects our shared commitment to supporting the Company’s long-term growth and success following the completion of the Transaction," said Angela McElwee, Chair of Charlotte’s Web."I am honored to join the Board at a significant moment in the Company's evolution, and I look forward to contributing to Charlotte's Web's strategic objectives and supporting long-term value creation for all stakeholders," said Jeff Raborn.Mr. Raborn's appointment was made pursuant to BAT's right to designate a second member to the Board of Directors under the terms of the amended and restated investor rights agreement dated May 28, 2026 and brings the total number of Directors to seven.About Charlotte's Web Holdings, Inc.Charlotte's Web Holdings, Inc., a Certified B Corporation headquartered in Louisville, Colorado, is a botanical wellness innovation company and a market leader in hemp extract wellness that includes Charlotte's Web whole-plant full-spectrum CBD extracts as well as broad-spectrum CBD and cannabinoid isolates. The Company's hemp extracts have naturally occurring botanical compounds including cannabidiol ("CBD"), CBN, CBC, CBG, THC, terpenes, flavonoids, and other beneficial compounds. Charlotte's Web product categories include CBD oil tinctures (liquid products), CBD gummies (sleep, calming, exercise recovery, immunity), CBN gummies, hemp-derived THC microdose gummies, functional mushroom gummies, CBD capsules, CBD topical creams, and lotions, as well as CBD pet products for dogs. Through its substantially vertically integrated business model, Charlotte's Web maintains stringent control over product quality and consistency with analytic testing from soil to shelf for quality assurance. Charlotte's Web products are distributed to retailers and healthcare practitioners throughout the U.S.A. and are available online through the Company's website at www.charlottesweb.com.Shares of Charlotte's Web trade on the Toronto Stock Exchange (TSX) under the symbol "CWEB" and are quoted in U.S. Dollars in the United States on the OTCQX under the symbol "CWBHF". Subscribe to Charlotte's Web investor news.For more information:Cory Pala
Director of Investor Relations
(720) 484-8930
Cory.Pala@CharlottesWeb.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/299722 Original: Charlotte's Web Appoints Jeff Raborn to Board of Directors
Wolf-man jack
1週前
WQLF SAYS: Look for the Price per Share of Charlottes Web stock to fall to the $.21 cents level in the near future when the 110 Million Outstanding Shares are added. It is ALL about Market Capilisation YQU Now Understand YQU Understand. Have Mercy WQLF ahoooooo
Dr. Joong J Fang Said: It might be called Bashing , But in reality it's called posting the Facts.
Q: How many outstanding shares when Charlottes Web reached its market cap in 2025?
Ai Generated:
Charlotte's Web Holdings Inc. had 159,107,206 shares outstanding when it reached its 2025 year-end market capitalization of approximately $54.22 million.2025 Quarterly Outstanding Shares Breakdown:Q1 2025: 158,009,541 sharesQ2 2025: 158,617,767 sharesQ3 2025: 159,107,206 sharesQ4 2025: 159,420,141 shares.
Q:How many shares outstanding shares when Charlottes Web reached its market cap in 2025. With the additional 110 million outstanding shares added, what will the market cap be at the current price per share?
Ai Generated:
At the end of 2025, Charlotte's Web Holdings, Inc. (CWBHF) had 159,107,206 shares outstanding, bringing its year-end market capitalization to approximately $57.62 million.With the additional 110 million common shares added through the British American Tobacco (BAT) debt conversion transaction, the new market cap at the current price of $0.4987 per share will be $134.20 million.Breakdown of the Calculations2025 Base Shares Outstanding: 159,107,206 shares (some recent listing platforms track up to 160,610,000 shares)Additional Shares Added: 110,000,000 sharesTotal Post-Transaction Shares: 269,107,206 shares (or up to 270,610,000 shares)Current Stock Price: $0.4987 per sharePro-Forma Market Cap ScenariosUsing Year-End Base: 269,107,206 shares × $0.4987 = $134,203,764Using Latest Tracking Base: 270,610,000 shares × $0.4987 = $134,953,207This structural increase in equity and market cap directly stems from the strategic deal converting C$75.3 million of outstanding BAT convertible debentures into equity, effectively purging $65 million in debt from Charlotte's Web's balance sheet.
Q:With the additional 110 million outstanding shares added by Charlottes Web . What price per share would have to match its $57.62 Market Cap ?
Ai Generated:
To match a \(\$57.62\text{M}\) market cap with roughly \(270.5\text{M}\) total outstanding shares (post-BAT transaction), the required share price would be approximately \(\$0.21\) per share.Here is the straightforward breakdown of the math:\(\frac{\text{Market\ Capitalization}}{\text{Total\ Shares\ Outstanding}}=\text{Price\ per\ Share}\)\(\frac{\$57,620,000}{270,549,931}\approx \$0.213\)Context:The New Shares: In late May 2026, Charlotte's Web completed a major debt-to-equity and private placement transaction with British American Tobacco (BAT), which added roughly 110 million shares to the float.
Q:Why is Market Capilisation important?
Ai Generated:
Market capitalization is the total dollar value of a company's outstanding shares. It is important because it provides a real-time, public snapshot of a company’s overall size, serves as a direct indicator of investment risk, and dictates whether a company fits your personal portfolio goals.1. Gauging Risk and Return PotentialMarket cap typically corresponds to a company's business stage. Investors use it to establish baseline expectations:Large-Cap (e.g., $10 Billion+): These are established industry leaders. They are generally less volatile, offer more stable revenue streams, and often pay dividends, making them lower-risk.Mid-Cap (e.g., $2 to $10 Billion): These companies are often growing but still working to disrupt larger competitors. They offer a balance of growth potential and moderate volatility.Small-Cap (e.g., $250 Million to $2 Billion): These are younger or niche companies. They possess the potential for rapid growth, but are highly vulnerable to economic downturns and carry higher volatility.2. Maintaining a Balanced PortfolioUnderstanding market cap helps you build a diversified portfolio. A well-rounded strategy might include safer, large-cap "anchor" stocks alongside smaller-cap stocks poised for aggressive growth.3. Comparing Company MetricsYou cannot evaluate a company's financial metrics (like revenue or debt) in a vacuum. Looking at raw numbers (e.g., "$100 million in sales") means very little until you compare it to the market cap. Market cap provides the context needed to see if a company is trading at a premium or a discount compared to its direct peers in the same sector.4. Acquisition and ValuationFor buyers and mergers, market cap helps immediately quantify the minimum amount of capital required to take over a company. However, it only represents equity value; acquirers must also look at Enterprise Value, which includes debt and cash, to determine a company's true takeover price.Note: Market cap is calculated by multiplying the current share price by the total number of outstanding shares
Because stock prices fluctuate constantly, market cap provides an up-to-the-minute valuation of what the public thinks the company is worth
Wolf-man jack
1週前
WQLF SAYS: Charlottes Web GRSS Status with their Genetic Seeds is Useless YQU Now Understand YQU Understand. LoLlipops 🍭 🍭. Have Mercy WQLF ahoooooo
Q: Impact of Cultivar Variability Inconsistency in Safety: Charlotte's Web' GRAS determination may be questioned due to the variability in hemp cultivars used across different batches. Each cultivar can have different chemical profiles, which may affect the safety and efficacy of the final product. Challenges in Meeting GRAS Criteria: The requirement for a consensus among experts on safety can be complicated by this variability. If different batches contain different cultivars, it may be difficult to ensure that all batches consistently meet the safety standards necessary for GRAS status. Conclusion The variability in hemp cultivars used by Charlottes Web could undermine the reliability of their GRAS determination. This inconsistency raises concerns about whether the product can consistently meet the safety criteria required for GRAS designation?
Ai Generated:
Cultivar variability is a major hurdle in the hemp and CBD industry. Without strict genetic standardization, natural fluctuations in chemical profiles complicate the consensus required for Generally Recognized As Safe (GRAS) status, ultimately undermining regulatory and consumer confidence in batch-to-batch consistency.The specific challenges include:1. The GRAS Standard and the FDATo achieve GRAS designation for food or dietary ingredients, a company must provide scientific data that proves a "reasonable certainty of no harm." Because hemp extracts are complex mixtures of cannabinoids, terpenes, and flavonoids, their safety profiles can shift if the starting plant material changes.Self-Affirmed vs. FDA: While Charlotte's Web secured a self-affirmed GRAS status in 2020 through a panel of experts, the U.S. Food and Drug Administration (FDA) has historically rejected broader applications for CBD as a dietary supplement, citing a lack of rigorous safety and toxicity data.The "Drug" Exclusion: The FDA's stance is also complicated by the fact that the purified CBD drug Epidiolex was already authorized for investigation, making it difficult for commercial extracts to navigate standard supplement pathways.2. Environmental and Genetic VariablesGenetic Drift: Even when relying on seed-grown plants or clones, genetic drift can cause commercial strains to fluctuate in their cannabinoid levels by 10% to 30%.Environmental Factors: CBD and other phytochemical yields depend heavily on variables like temperature, soil composition, and harvest timing. These external factors naturally cause batch-to-batch inconsistencies.Varietal Standardization: Cultivars are not static. While brands like Charlotte's Web have focused on the scientific breeding and patenting of stabilized proprietary varietals to lock in phytochemical consistency, natural agricultural variability remains a primary concern for regulators.3. Broader International and Legislative RoadblocksThe safety of CBD extracts from major U.S. brands faces international scrutiny. For instance, the European Food Safety Authority (EFSA) formally rejected a safety submission for Cannabis sativa L. carbon dioxide extracts, indicating that a universal safety standard for these products "cannot be established" at this time.
Wolf-man jack
1週前
WQLF SAYS: Look for the Price per Share of Charlottes Web stock to fall to the $.21 cents level in the near future when the 110 Million Outstanding Shares are added. It is ALL about Market Capilisation YQU Now Understand YQU Understand. Have Mercy WQLF ahoooooo
Dr. Joong J Fang Said: It might be called Bashing by FANG FANG. But in reality it's called posting the Facts.
Q: How many outstanding shares when Charlottes Web reached its market cap in 2025?
Ai Generated:
Charlotte's Web Holdings Inc. had 159,107,206 shares outstanding when it reached its 2025 year-end market capitalization of approximately $54.22 million.2025 Quarterly Outstanding Shares Breakdown:Q1 2025: 158,009,541 sharesQ2 2025: 158,617,767 sharesQ3 2025: 159,107,206 sharesQ4 2025: 159,420,141 shares.
Q:How many shares outstanding shares when Charlottes Web reached its market cap in 2025. With the additional 110 million outstanding shares added, what will the market cap be at the current price per share?
Ai Generated:
At the end of 2025, Charlotte's Web Holdings, Inc. (CWBHF) had 159,107,206 shares outstanding, bringing its year-end market capitalization to approximately $57.62 million.With the additional 110 million common shares added through the British American Tobacco (BAT) debt conversion transaction, the new market cap at the current price of $0.4987 per share will be $134.20 million.Breakdown of the Calculations2025 Base Shares Outstanding: 159,107,206 shares (some recent listing platforms track up to 160,610,000 shares)Additional Shares Added: 110,000,000 sharesTotal Post-Transaction Shares: 269,107,206 shares (or up to 270,610,000 shares)Current Stock Price: $0.4987 per sharePro-Forma Market Cap ScenariosUsing Year-End Base: 269,107,206 shares × $0.4987 = $134,203,764Using Latest Tracking Base: 270,610,000 shares × $0.4987 = $134,953,207This structural increase in equity and market cap directly stems from the strategic deal converting C$75.3 million of outstanding BAT convertible debentures into equity, effectively purging $65 million in debt from Charlotte's Web's balance sheet.
Q:With the additional 110 million outstanding shares added by Charlottes Web . What price per share would have to match its $57.62 Market Cap ?
Ai Generated:
To match a \(\$57.62\text{M}\) market cap with roughly \(270.5\text{M}\) total outstanding shares (post-BAT transaction), the required share price would be approximately \(\$0.21\) per share.Here is the straightforward breakdown of the math:\(\frac{\text{Market\ Capitalization}}{\text{Total\ Shares\ Outstanding}}=\text{Price\ per\ Share}\)\(\frac{\$57,620,000}{270,549,931}\approx \$0.213\)Context:The New Shares: In late May 2026, Charlotte's Web completed a major debt-to-equity and private placement transaction with British American Tobacco (BAT), which added roughly 110 million shares to the float.
Q:Why is Market Capilisation important?
Ai Generated:
Market capitalization is the total dollar value of a company's outstanding shares. It is important because it provides a real-time, public snapshot of a company’s overall size, serves as a direct indicator of investment risk, and dictates whether a company fits your personal portfolio goals.1. Gauging Risk and Return PotentialMarket cap typically corresponds to a company's business stage. Investors use it to establish baseline expectations:Large-Cap (e.g., $10 Billion+): These are established industry leaders. They are generally less volatile, offer more stable revenue streams, and often pay dividends, making them lower-risk.Mid-Cap (e.g., $2 to $10 Billion): These companies are often growing but still working to disrupt larger competitors. They offer a balance of growth potential and moderate volatility.Small-Cap (e.g., $250 Million to $2 Billion): These are younger or niche companies. They possess the potential for rapid growth, but are highly vulnerable to economic downturns and carry higher volatility.2. Maintaining a Balanced PortfolioUnderstanding market cap helps you build a diversified portfolio. A well-rounded strategy might include safer, large-cap "anchor" stocks alongside smaller-cap stocks poised for aggressive growth.3. Comparing Company MetricsYou cannot evaluate a company's financial metrics (like revenue or debt) in a vacuum. Looking at raw numbers (e.g., "$100 million in sales") means very little until you compare it to the market cap. Market cap provides the context needed to see if a company is trading at a premium or a discount compared to its direct peers in the same sector.4. Acquisition and ValuationFor buyers and mergers, market cap helps immediately quantify the minimum amount of capital required to take over a company. However, it only represents equity value; acquirers must also look at Enterprise Value, which includes debt and cash, to determine a company's true takeover price.Note: Market cap is calculated by multiplying the current share price by the total number of outstanding shares
Because stock prices fluctuate constantly, market cap provides an up-to-the-minute valuation of what the public thinks the company is worth
Wolf-man jack
1週前
WQLF SAYS: In comparison, Charlottes Web can sustain 1.8 To 2 Quarters of Operational Runway. CV SCIENCES on the other hand, can sustain 1 To 3 Quarters of Operational Runway. With the inflow of $10 Million dollars Charlottes Web can sustain 5.8 Quarters of Operational Runway. In order for CV SCIENCES to match and surpass the Itsy bitsy spider Web company, CV SCIENCES will need to get a loan for $600,000 Dollars from its current Loan provider. $600,000 to $10,000,000 is a big difference YQU Now Understand YQU Understand. CWBHF last Quarter was a loss of $0.08 cents per share with 159, 420,121 outstanding shares. CV SCIENCES has a better track record with a break even $0.00 per share. Now YQU Understand YQU Understand. Have Mercy WQLF ahoooo
Q: How many Quarters can Charlottes Web sustain with current Cash on hand and the Current Amount of Revenues?
Ai Generated:
Charlotte's Web (CWEB) has approximately 1.8 to 2.0 quarters of operational runway remaining based on current metrics. The company reported $5.2 million in cash reserves and $11.2 million in Q1 2026 revenue, while experiencing an operating cash burn of $2.8 million for the quarter.Q1 2026 Financial BreakdownCash & Cash Equivalents: $5.2 millionQ1 2026 Revenues: $11.2 millionNet Cash used in Operating Activities: $2.8 millionAdjusted EBITDA Loss: $1.7 millionSustainability & Runway CalculationQuarterly Burn Rate: $2.8 million operating cash burnRunway Calculation: \(\$5.2 \text{ million} \div \$2.8 \text{ million/quarter} \approx 1.85 \text{ quarters}\)Alternative burn (EBITDA): \(\frac{\$5.2 \text{ million}}{\$1.7 \text{ million/quarter}} \approx 3.05 \text{ quarters}\)While the remaining cash and equivalents cover less than two quarters of operations at the current rate of operating cash depletion, Charlotte's Web is actively working on proposals to convert a large convertible debenture and secure additional equity investments to eliminate major debt and extend cash runway.
Q: How many Quarters can CV SCIENCES sustain with current Cash on hand and the Current Amount of Revenue?
Ai Generated:
CV Sciences (OTCQB: CVSI) currently has $0.3 million in cash on hand. Based on recent Q1 2026 financial results—which showed $3.2 million in revenue, a net loss of $0.643 million, and positive operating cash flow of ~$0.1 million—the company's current cash reserves can sustain operations for approximately 1 to 3 additional quarters, depending on the metric used:Cash from operations: $0.00 / (positive operating cash flow) = Indefinite (cash flow breakeven).Net loss burn rate: \(\$300,000 \div \$643,000\) (quarterly net loss) = \(\approx 0.46\) quarters.Operating loss burn rate: \(\$300,000 \div \$318,000\) (quarterly operating loss) = \(\approx 0.94\) quarters.Context on Sustainability:CV Sciences' low cash-to-burn ratio is typical for a micro-cap CBD company. To extend its cash runway, the company is aggressively reducing operating expenses (down 13.3% year-over-year) and focusing on high-margin, non-cannabinoid product lines under the Plus Health brand. Despite the tight liquidity, management projects to achieve cash flow break-even in 2026.
Q: How many Quarters can Charlottes Web sustain with current Cash on hand and the Current Amount of Revenue and the 10 million dollars from BAT ?
Ai Generated:
Based on its recent cash burn rate, Charlotte’s Web can sustain itself for approximately 5.4 quarters (roughly 16 months) using its current cash, current revenue, and the $10 million British American Tobacco (BAT) equity injection. However, management officially states that this transaction provides enough liquidity to fund operations for the next 4 quarters (12 months).Financial Position OverviewThe baseline financial numbers from the Charlotte's Web Q1 2026 Financial Results and recent filings indicate:MetricFinancial FigureCash on Hand (As of March 31, 2026)$5.2 MillionBAT Cash Injection (Closed May 28, 2026)$10.0 MillionTotal Pro-Forma Cash Available$15.2 MillionCurrent Quarterly Revenue (Q1 2026)$11.2 MillionQuarterly Net Cash Operating Burn$2.8 MillionStep-by-Step Runway CalculationAggregate total cash assets: Add the $5.2 million baseline cash to the incoming $10 million BAT private placement to get $15.2 million.Determine net cash burn rate: Use the net cash used in operating activities, which was $2.8 million for Q1 2026.Divide total cash by burn rate: $15.2 million divided by $2.8 million equals 5.43 quarters.Strategic Blind Spots & ConsiderationsMedicare Pilot Spending: Cash is primarily earmarked to fund the upcoming CMMI Medicare pilot program, which may temporarily accelerate spending.Debt Elimination Savings: The BAT transaction converted $65 million of debt into equity, eliminating roughly $3 million in annual interest payments ($750k saved per quarter).SG&A Containment: Core SG&A expenses are expected to normalize between $10 million and $11 million per quarter, keeping overhead lean.
Wolf-man jack
1週前
WQLF SAYS: Nice try. Misinformation, Disinformation and BS cannot escape the Facts WE Now Understand YQU Understand. Charlottes Web 's Genetic Seeds didn't get past the U.K's Smell Test. We Now Understand YQU Understand LoLlipops 🍭 🍭 Have Mercy WQLF ahoooooo
The made up So Called Fact Sheet of Disinformation By the Misinfomer Said:
CV Sciences — Does not disclose cultivar because they don’t use a single cultivar.
Pure BS and Disinformation ¥¥
Q: Does CV SCIENCES utilize cultivar hemp?
Ai Generated:
Yes. CV Sciences (makers of the +PlusCBD brand) utilizes specific agricultural hemp cultivars for their products.They use a hybrid sourcing approach that combines premium EU-certified hemp seeds/cultivars with high-quality domestic U.S. cultivars (such as those grown on small farms in Kentucky) to blend their full-spectrum oils.
You can learn more about their sourcing on the CV Sciences FAQ page
.
Q: Microsoft CoPilot Compare Charlotte's Web vs CV Sciences sourcing.
Ai Generated:
When comparing the hemp sourcing strategies of Charlotte's Web and CV Sciences using Microsoft Copilot, a clear distinction emerges between a vertically integrated "closed-loop" model and a hybrid global sourcing model.Charlotte's Web: Proprietary U.S. CultivationCharlotte's Web manages its supply chain closely, relying entirely on domestic agriculture and their own proprietary hemp genetics.Locations: Grown on sustainable, non-GMO farms in Colorado, Oregon, and Kentucky.Genetics: They utilize a patented hemp cultivar ("CW2A") designed to be high in CBD and low in THC.Extraction: They employ ethanol and CO2 extraction methods.Transparency: They implement rigorous soil testing and offer batch-specific Certificates of Analysis (COAs) via QR codes on product labels.Focus: Total vertical integration and whole-plant standardization.CV Sciences: Hybrid U.S. and EU SourcingCV Sciences (makers of +PlusCBD) relies on a mixed sourcing strategy, taking advantage of both domestic and international agriculture.Locations: They source from small farms in Kentucky, along with EU-certified hemp cultivated by experienced Dutch farmers.Approach: They use a hybrid of high-quality, full-spectrum oils from Europe and domestic cultivars to blend a consistent product.Extraction: They use CO2 extraction for their hemp extracts.Compliance: CV Sciences was the first company to attain Generally Recognized as Safe (GRAS) status for its hemp-derived CBD and follows cGMP manufacturing standards.Summary of DifferencesSourcing Footprint: Charlotte's Web is strictly 100% U.S.-sourced, while CV Sciences incorporates both U.S. and European/Dutch hemp into their supply chain.Genetics: Charlotte's Web focuses heavily on its own patented plant strains, whereas CV Sciences focuses on broad, long-standing European supplier relationships paired with U.S. partners.
Q: Did Charlotte's Web ever sell their CBD products in the United Kingdom?
Ai Generated:
Yes, Charlotte’s Web has sold its CBD products in the United Kingdom.They first entered the UK market in 2016 through a partnership with the distributor Savage Cabbage. In March 2022, Charlotte's Web signed an exclusive UK distribution agreement to expand the availability of their full-spectrum hemp extract oils, gummies, and capsules.To legally sell ingestible CBD in the UK, products must go through the UK Food Standards Agency’s (FSA) rigorous Novel Food authorization process. Charlotte's Web successfully validated their Novel Food applications with the FSA and their products were included on the agency's public list of approved CBD products
For the most up-to-date information on which specific formulas are currently available and cleared for sale in England and Wales, you can review the official FSA Register of CBD Products Linked to Novel Food Applications.
Latest Update. ALL SUCCESSFUL 52 APPLICATIONS INCLUDING Savage Cabbage White Label Charlottes Web products were ALL DECLINED.
DarthYoda
1週前
Microsoft CoPilot Compare Charlotte's Web vs CV Sciences sourcing...
Takeaway: Charlotte’s Web and CV Sciences could not be more different in how they source hemp. One is a vertically integrated, cultivar-driven, U.S.-grown operation. The other is a commodity-extract importer relying on blended European industrial hemp. The sourcing difference alone explains why their products, consistency, and reputations diverge so sharply.
Below is a direct, structured, side-by-side comparison with no fluff — just the facts.
🌱 Charlotte’s Web vs CV Sciences: Sourcing Comparison
1. Genetics & Cultivar Transparency
Charlotte’s Web — Uses a proprietary, registered hemp cultivar (CW1AS1).
Known genetics
Consistent cannabinoid ratios
Grown specifically for high-CBD resin
Full transparency
CV Sciences — Does not disclose cultivar because they don’t use a single cultivar.
Biomass is sourced from multiple EU farms
Likely industrial hemp varieties (Futura 75, Fedora 17, Finola, etc.)
No genetic consistency
No cultivar transparency
Winner: Charlotte’s Web — by a mile.
2. Where the Hemp Is Grown
Charlotte’s Web
Grown in Colorado and other U.S. states
Controlled, domestic supply chain
Soil, water, and pesticide transparency
Farm-to-bottle traceability
CV Sciences
Biomass and crude extract imported from Europe
Often from fiber/seed hemp farms
No farm-level transparency
No single-origin traceability
Winner: Charlotte’s Web — full domestic control.
3. Type of Hemp Used
Charlotte’s Web
High-resin hemp flower
Cultivated specifically for cannabinoid extraction
Rich terpene and minor cannabinoid profile
CV Sciences
Industrial hemp biomass
Often grown for fiber or seed
Lower resin content
Requires large volumes to extract meaningful CBD
Leads to darker, crude initial extract
Winner: Charlotte’s Web — uses resin-rich flower, not commodity biomass.
4. Extraction Input Quality
Charlotte’s Web
Uses fresh, resinous flower
Controlled harvest and drying
Clean, food-grade input material
CV Sciences
Uses bulk crude extract imported in drums
Material is homogenized from multiple farms
Appearance resembles “sludge” because it’s crude resin
Historically criticized (2014 Project CBD report) for low-grade input
Winner: Charlotte’s Web — higher-grade raw material.
5. Vertical Integration
Charlotte’s Web
Seed-> cultivation-> harvest-> extraction-> formulation-> product
Full control over every step
Consistency and traceability
CV Sciences
Outsourced cultivation
Outsourced extraction
Imports crude extract
Only controls final formulation and bottling
Winner: Charlotte’s Web — complete vertical integration.
6. Transparency
Charlotte’s Web
Discloses cultivar
Discloses growing regions
Discloses farming practices
Batch-level COAs
Publicly registered genetics
CV Sciences
Does not disclose cultivar
Does not disclose farms
Does not disclose extraction partners
COAs only show final product, not raw material origin
Winner: Charlotte’s Web — significantly more transparent.
7. Likelihood of Fiber-Grade or Retting-Related Material
Charlotte’s Web
Zero — they grow cannabinoid-rich flower, not fiber hemp.
CV Sciences
High likelihood of fiber-grade cultivars
No evidence of retting today, but:
EU hemp is often grown for fiber
Biomass is low-resin
Crude extract is dark and unrefined
Supply chain is opaque
This is why the “retted hemp” rumor persists
Winner: Charlotte’s Web — no ambiguity.
🧾 Summary Table
Category: Charlotte’s Web vs CV Sciences
Cultivar: Proprietary CW1AS1 vs Undisclosed EU industrial hemp
Origin: U.S. farms vs Europe (multiple farms)
Input Material: High-resin flower vs Industrial hemp biomass
Transparency: High vs Low
Vertical Integration: Full vs Partial
Consistency: High vs Variable
Risk of Fiber-Grade Input: None vs Moderate
Evidence of Retting: None vs No proof, but historical concerns
🎯 Final Verdict
Charlotte’s Web is a premium, vertically integrated, cultivar-driven CBD producer.
CV Sciences is a commodity-extract importer using blended European industrial hemp.
This is not a small difference — it’s the entire foundation of product quality.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Fangster
21時間前
rstar
1週前
メールアドレスで登録
